Q-omics provides the consensus-scored BANF1 profile across patient tissues and cancer cell-line models. BANF1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BANF1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, BANF1 protein abundance shows 27,964 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where BANF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BANF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BANF1 survival associations across molecular data types. BANF1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BANF1 RNA expression–survival associations across cancer types. High BANF1 expression shows unfavorable associations in ACC, HNSC, KIRC, LIHC, LUAD and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BANF1 RNA expression.
This table summarizes BANF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BANF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BANF1 shows higher tumor expression in HNSC, KIRP, LIHC, STAD, LUSC and COAD. The HNSC box plot shows higher BANF1 RNA expression in tumor versus normal tissue (log2 FC = +1.047, t-test p < 0.001).
This table shows molecular features associated with BANF1 in patient tissues and cancer cell lines. In patient samples, BANF1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, BANF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
